#USA #New York #Securities Fraud #Pomerantz LLP #Nektar Therapeutics

Pomerantz Law Firm Investigates Nektar Therapeutics

Pomerantz LLP, one of the leading law firms specializing in corporate and securities class action litigation, has initiated an investigation on behalf of investors of Nektar Therapeutics (NASDAQ: NKTR). This inquiry aims to assess whether the company and its officers or directors engaged in any unlawful business practices or securities fraud.

Background

On December 16, 2025, Nektar disclosed disappointing results from the Phase 2b REZOLVE-AA trial, which involved the investigational drug rezpegaldesleukin—a novel IL-2 pathway agonist aimed at treating specific medical conditions. The topline results indicated a failure to reach statistical significance and noted the inclusion of four patients who should not have been part of the study.

Following the announcement, Nektar's stock plummeted by 7.77%, translating to a loss of $4.14 per share, closing at $49.16. This dramatic downturn raised alarms among investors, prompting Pomerantz LLP to step in and investigate the circumstances surrounding the trial results and how they were communicated to shareholders.

Investors' Concerns

Investors are advised to reach out to Danielle Peyton at Pomerantz LLP for further information on how they can be part of this investigation. The firm emphasizes the importance of shareholders being aware of any possible misconduct, especially in light of the recent decline in stock value following the troubling trial report.

Pomerantz LLP is recognized for its stellar reputation in the realm of class action lawsuits, having been established over 85 years ago by the renowned attorney Abraham L. Pomerantz, who is regarded as a pioneer in securities litigation. The firm prides itself on its history of securing significant damage awards for investors who have suffered as a result of corporate deception.

What to Do

Investors impacted by the news about Nektar Therapeutics are encouraged to contact Pomerantz LLP to discuss their legal options. By joining potential class action suits, investors may seek restitution for losses incurred as a result of any fraudulent actions committed by the company or its leadership.

Conclusion

The investigation into Nektar Therapeutics reflects a growing commitment by law firms to hold corporations accountable for their actions and ensure that investor rights are protected. As the landscape of biotechnology investments continues to evolve, keeping an eye on regulatory compliance and business ethics becomes increasingly important for safeguarding public trust and investor interests. For more information, visit Pomerantz Law Firm's website.